Diabetic Med:刚成年与1型糖尿病的关系?

2018-02-01 MedSci MedSci原创

近日,国际杂志 《Diabetic Med》上在线发表一项关于刚成年与1型糖尿病的关系----来自DAWN2研究的见解的研究。比较刚成年1型糖尿病成年人(18-30岁)与相关的年龄> 30岁的成年人的临床,心理,教育和社会变量。 参与者完成了一系列包括人口统计学和临床​​问题(合并症,低血糖)的调查,并验证了有关社会心理(健康影响,生活质量,信仰和态度,自我管理行为,医疗体验和家庭支持

近日,国际杂志 《Diabetic Med》上在线发表一项关于刚成年与1糖尿病的关系----来自DAWN2研究的见解的研究。比较刚成年1糖尿病成年人(18-30岁)与相关的年龄> 30岁的成年人的临床,心理,教育和社会变量。

参与者完成了一系列包括人口统计学和临床​​问题(合并症,低血糖)的调查,并验证了有关社会心理(健康影响,生活质量,信仰和态度,自我管理行为,医疗体验和家庭支持)的自我报告量表和糖尿病教育因素。与一些心理变量相比,刚成年的人与30岁以上的成年人不同。与30岁以上的成年人相比,刚成年的人报告的整体生活质量,社会支持和医疗团队的支持更好; 然而,刚成年的人经历了更多的糖尿病特有的痛苦,并且参与自我管理较少。糖尿病教育与一些指标有关,而歧视的经验是有害的,但这些影响在刚成年的人和30岁以上的成年人之间没有差异。对地理区域的分析表明,北美和欧洲刚成年的人的幸福感比年纪较大成年人好,而在亚洲结果则相反。

研究表明,刚成年的人,尤其25-30岁的成年人面临糖尿病特有的痛苦。需要新的干预措施来更有效地满足这些弱势成年人的需求。

原始出处:

M. Vallis, I. Willaing and R. I. G. Holtet al. Emerging adulthood and Type 1 diabetes: insights from the DAWN2 Study

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1760512, encodeId=a60e1e6051243, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Nov 29 18:26:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970572, encodeId=56e419e0572b7, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue Sep 25 22:26:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638392, encodeId=9ba9163839294, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 08 05:26:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608510, encodeId=cbd616085101c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 03 04:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284178, encodeId=95112841e8e7, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 01 14:31:00 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1760512, encodeId=a60e1e6051243, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Nov 29 18:26:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970572, encodeId=56e419e0572b7, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue Sep 25 22:26:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638392, encodeId=9ba9163839294, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 08 05:26:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608510, encodeId=cbd616085101c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 03 04:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284178, encodeId=95112841e8e7, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 01 14:31:00 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1760512, encodeId=a60e1e6051243, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Nov 29 18:26:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970572, encodeId=56e419e0572b7, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue Sep 25 22:26:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638392, encodeId=9ba9163839294, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 08 05:26:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608510, encodeId=cbd616085101c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 03 04:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284178, encodeId=95112841e8e7, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 01 14:31:00 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1760512, encodeId=a60e1e6051243, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Nov 29 18:26:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970572, encodeId=56e419e0572b7, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue Sep 25 22:26:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638392, encodeId=9ba9163839294, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 08 05:26:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608510, encodeId=cbd616085101c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 03 04:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284178, encodeId=95112841e8e7, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 01 14:31:00 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1760512, encodeId=a60e1e6051243, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Nov 29 18:26:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970572, encodeId=56e419e0572b7, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Tue Sep 25 22:26:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638392, encodeId=9ba9163839294, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 08 05:26:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608510, encodeId=cbd616085101c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 03 04:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284178, encodeId=95112841e8e7, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Feb 01 14:31:00 CST 2018, time=2018-02-01, status=1, ipAttribution=)]
    2018-02-01 神功盖世

    0

相关资讯

JAMA:普通牛奶奶粉不会增加婴幼儿糖尿病风险

一项长达15年的多国研究发现,1型糖尿病遗传易感婴幼儿可以放心喝由牛奶制成的普通配方奶粉,这不会增加他们罹患1型糖尿病的风险。

JCEM:1型糖尿病患者从连续血糖监测获益几何?

大家都知道1型糖尿病患者(T1D)实时连续血糖监测(RT-CGM)的随机对照试验显示其改善血糖控制,但目前关于实际应用的数据还很有限。为了评估RT-CGM在实际应用中对于血糖控制、住院工、作旷工和生活质量(QOL)的影响,Sara Charleer等人进行了相关研究,并把研究结果发表在近日的JCEM杂志上。

1型糖尿病:我国患者近千万 规范管理有三难

2018年1月4日,中华医学会糖尿病学分会前任主任委员、中山大学附属第三医院教授翁建平组建的研究小组在《英国医学杂志》上发表一项研究成果,不仅揭示我国1型糖尿病整体发病情况,还填补我国1型糖尿病数据地图的空白。旨在介绍此项研究成果,加强我国1型糖尿病管理的工作规范,2018年1月7日,《健康报》社在京主办1型糖尿病防治知识新闻传播研讨会,国家卫计委医政医管局医疗与护理处张萌主任,与翁建平、中华医学

Lancet diabetes endo:30岁以上人群也可患1型糖尿病。

1型糖尿病好发于儿童和青少年。已明确年轻发病的1型糖尿病具有遗传易感性,且不会发展成2型糖尿病。目前尚不清楚,1型糖尿病的遗传易感性,在30岁以后,导致糖尿病诊断的贡献度。现有研究人员研究在60岁内由高遗传易感性导致的1型糖尿病的概率和表型。Nicholas J Thomas等人开展一横断面分析,运用一种基于29种常见变异的1型糖尿病遗传风险评分,以确定英国的有或高或低患1型糖尿病的遗传易感风险的

BMJ:中国1型糖尿病的发病率分析!

由此可见,在中国大多数的新发1型糖尿病病例为成人。中国儿童1型糖尿病的发病率在这个研究报告中是最低的。

Diabetes Care:1型糖尿病患者微血管病因与心血管疾病之间相关性的差异!

由此可见,1型糖尿病和CKD患者无PDR与心血管疾病患病率降低相关,提示可能存在PDR和CVD的常见保护因素。